Navigation Links
Vaccine to quit smoking?

Well, there is aren’t too many approaches which have not been taken in trying to prevent smoking, but a new vaccine developed by Nabi,// a pharmaceutical company, promises new hope in preventing people from relapsing. The vaccine (NicVAX) binds nicotine and prevents it from reaching the brain, where it causes its stimulatory effects. In animal control experiments, the vaccine was effective in preventing brain distribution of nicotine. For India? We need a Beedi Vaccine!
'"/>




Page: 1

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Vaccine for Alzheimer’s diseas
3. Health Officials Recommend Flu Vaccine
4. Smallpox Vaccine May Help Fight Cervical Cancer
5. Panacea Biotech To Market Anthrax Vaccine
6. New Prostate Cancer Vaccine Shows Promise
7. Drug Firm Offers to Donate Smallpox Vaccine
8. Vaccine guards against shingles
9. Vaccine for septic conditions
10. A new Vaccine for Pneumonia
11. Vaccine Reduces antibiotic-resistant infections in Children
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vaccine quit smoking

(Date:5/16/2008)...ns of Children Still in Danger, NEW YORK, May 16 ...dvertising Council today announced a partnership t...ic service announcements (PSAs) filmed by A-List,c... Joel Madden, David,Duchovny, Tea Leoni, and Paul ...r cyclone. The Ad Council is distributing the new ...
(Date:5/16/2008)...wswire-FirstCall/ -- Nationwide,Health Properties,...of David,M. Boitano to Senior Vice President and S...ous contribution to NHP over the last several year... diversification strategy,successes. Dave has been...stments for NHP, leveraging his vast experience an...
(Date:5/16/2008)...Call/ -- CryoCor, Inc. (Nasdaq:,CRYO), a medical d...arrhythmias, announced today that on May 8, 2008, ...a complaint in the Superior Court of the State,of ...nts each member of the,Board of Directors of CryoC... complaint is styled Secondido, et al. v. CryoCor,...
(Date:5/16/2008)...ed to community physicians, audit finds , ...s between major academic cancer centers and commun...ead cancer treatment advances, say researchers at ... new cancer treatments are created at major academ...munity hospitals, noted the researchers, who condu...
Breaking Medicine News(10 mins):Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2
...th crisis in the Palestinian territory following t...he UN health agency has called for urgent action b...n of basic medical services. "The crisis is seriou...tinian Ministry of Health to deliver critical heal...
...apathy, has been appointed honorary consultant and...vices in speciality of plastic, hand and reconstru...ead of the Department of surgery in Ganga Medical ...consultation and perform major operations to membe...
...od protein levels are found to be associated with ...es// , metabolic syndrome and cardiovascular disea...inding protein 4 (RBP4), when reduced by the effec...s proved to drop the risk factors of diabetes – fi...
...issioned by The Globe and Mail and CTV News it is ...rans fats that are among the highest in the world/...When surveyed the different outlets of fast foods ...it was found that the amount of trans fat in these...
Other Medicine News:Health News:A Carrier Protein Associates With Human Insulin Resistance 2
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference 7187 1STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference 7187 2UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 1UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 2UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy 7185 3Nutraceutical Reports 2007 Fiscal Year End Results 7183 1Nutraceutical Reports 2007 Fiscal Year End Results 7183 2Nutraceutical Reports 2007 Fiscal Year End Results 7183 3Nutraceutical Reports 2007 Fiscal Year End Results 7183 4Nutraceutical Reports 2007 Fiscal Year End Results 7183 5Nutraceutical Reports 2007 Fiscal Year End Results 7183 6Medco Announces Two For One Stock Split 7181 1Medco Announces Two For One Stock Split 7181 2Medco Announces Two For One Stock Split 7181 3Medco Announces Two For One Stock Split 7181 4Medco Announces Two For One Stock Split 7181 5
...ented at the ASCO Cancer Conference, NORTH HOLLYWO.../,-- The International Myeloma Foundation (IMF)-su...y and support for myeloma patients,families, rese...,follow-up to a Phase 3 multi- national clinical t...E(R) improves the probability of,survival by 41%. ...
...ANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros...ne results of a,six month U.S. Phase 3 study of An...e normal testicular function in men with,secondary...inferiority in all the endpoints of the study, com... treatment for low,testosterone., Study Details an...
Other Medicine Technology:Study Shows Velcade Plus Doxil Improves Survival in Previously,Treated Patients With Multiple Myeloma 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 3Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 4Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 5
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio
Magnetic separation is a method for isolating antibodies, antigens, lectins, enzymes, nucleic acids and cells using affinity binding, while retaining biological activity. Streptavidin has been coated
1 m Dynabeads with covalently bound recombinant streptavidin, allowing capture of any biotinylated target. The Dynabeads® MyOne™ have a large surface area, high capacity, magnetic pull and
Medicine Products: